STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp - INCY STOCK NEWS

Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.

Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.

The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.

Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.

Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.

News

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Rhea-AI Summary
Incyte and China Medical System Holdings have entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases in Asia. Incyte will receive upfront payment, potential milestones, and royalties, while CMS gains exclusive rights for development and commercialization in certain countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Incyte (INCY) granted equity inducement awards to the new Executive Vice President and General Manager of U.S. Dermatology, Matteo Trotta. The awards include 7,828 restricted stock units and stock options to purchase 21,868 shares of common stock. The RSUs vest over four years, while the stock options have a ten-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
News

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

Rhea-AI Summary
Incyte (INCY) announced positive results from a Phase 2 study on povorcitinib for prurigo nodularis treatment at AAD Annual Meeting. The study met primary and secondary endpoints, showing significant improvement in itch scores. Povorcitinib demonstrated potential as an effective treatment with well-tolerated safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
News

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Rhea-AI Summary
Incyte (INCY) announces positive results from a Phase 2 study on ruxolitinib cream for hidradenitis suppurativa at AAD Annual Meeting. The study met its primary endpoint, demonstrating significant reduction in abscess and inflammatory nodule count compared to the vehicle control. Secondary endpoints also showed promising results, with a high percentage of patients achieving reductions in AN count. Ruxolitinib cream was well-tolerated with few adverse events. These results indicate the potential for ruxolitinib cream as an effective treatment option for patients with milder HS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
-
News

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Rhea-AI Summary
Incyte (INCY) announces multiple abstracts featuring data from its dermatology portfolio to be presented at the 2024 AAD Annual Meeting. Key highlights include ruxolitinib cream and povorcitinib studies in various dermatologic conditions. Late-breaking abstracts on prurigo nodularis and hidradenitis suppurativa to be presented. Analyst and investor event scheduled for March 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
News

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

Rhea-AI Summary
Incyte launches The Unseen Journey program using AI to visually depict the impact of myeloproliferative neoplasms (MPNs) on patients. The program transforms patient experiences into unique images to raise awareness and empathy for those with MPNs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
AI
News

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

Rhea-AI Summary
Incyte's axatilimab receives Priority Review acceptance for chronic GVHD treatment after positive AGAVE-201 trial results, showing promising efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conference

Rhea-AI Summary
Incyte (INCY) to present at Cowen 44th Annual Health Care Conference on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
-
News

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

Rhea-AI Summary
Incyte (INCY) reports strong FY'23 with total net product and royalty revenues of $3.7 billion, a 14% increase YoY. Key highlights include Jakafi net revenues of $2.6 billion (+8%) and Opzelura cream net revenues of $109 million in Q4'23. The company aims for over 10 new launches by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
earnings
News

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none

FAQ

What is the current stock price of Incyte (INCY)?

The current stock price of Incyte (INCY) is $72.11 as of February 21, 2025.

What is the market cap of Incyte (INCY)?

The market cap of Incyte (INCY) is approximately 13.8B.

What is Incyte Genomics Inc. known for?

Incyte Genomics Inc. is known for its development and commercialization of proprietary therapeutics, primarily focused on oncology and dermatology.

Where is Incyte Genomics Inc. headquartered?

Incyte Genomics Inc. is headquartered in Wilmington, Delaware.

What is Jakafi?

Jakafi is Incyte's lead drug, used to treat rare blood cancers and graft versus host disease, in collaboration with Novartis.

Which drugs has Incyte marketed?

Incyte has marketed drugs including Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma.

What is Opzelura used for?

Opzelura is Incyte’s first dermatology product, approved for atopic dermatitis in 2021 and for vitiligo in 2022.

Does Incyte collaborate with other pharmaceutical companies?

Yes, Incyte has established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of its compounds.

How many employees work at Incyte?

Incyte employs over 625 professionals.

What is Incyte's vision?

Incyte's vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs.

How can I get more information about Incyte?

More information about Incyte can be found on their corporate website at www.incyte.com.

What areas does Incyte's pipeline cover?

Incyte's pipeline includes a broad array of oncology and dermatology programs.
Stock INCY logo
Incyte Corp

Nasdaq:INCY

INCY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

13.81B
189.15M
2.05%
97.41%
2.62%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON